Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On November 13, 2024, Cocrystal Pharma, Inc. (COCP) announced financial results for the third quarter of 2024 and provided a business update.</li><li>Over the next few months, we anticipate multiple important catalysts for the company, including topline results from the Phase 2a trial of CC-42344 before the end of 2024, filing of an Investigational New Drug (IND) application in 2025 to conduct the next study of CC-42344 in the U.S., and topline results for the multiple-ascending dose (SAD) portion of the Phase 1 trial of CDI-988 in late 2024 or early 2025.</li><li>The company exited the third quarter of 2024 with unrestricted cash of approximately $13.0 million, which is enough to fund operations for at least the next 12 months.</li></ul>

On November 13, 2024, Cocrystal Pharma, Inc. (COCP) announced financial results for the third quarter of 2024 and provided a business update.Over the next few months, we anticipate multiple important catalysts for the company, including topline results from the Phase 2a trial of CC-42344 before the end of 2024, filing of an Investigational New Drug (IND) application in 2025 to conduct the next study of CC-42344 in the U.S., and topline results for the multiple-ascending dose (SAD) portion of the Phase 1 trial of CDI-988 in late 2024 or early 2025.The company exited the third quarter of 2024 with unrestricted cash of approximately $13.0 million, which is enough to fund operations for at least the next 12 months.

Cocrystal Pharma

COCP: Multiple Upcoming Catalysts